Availability of the revised financial statements for Sanofi excluding Opella

Paris, France – December 6, 2024. Following the press release on October 21, 2024 and the plan to transfer a 50% controlling stake in Opella (consumer healthcare division) to CD&R, the revised financial statements for Sanofi reflecting the new scope, excluding Opella, are now available on the "Investors" section of sanofi.com in one convenient spreadsheet file.

The adjustments to the financial statements reclassify Opella’s business as discontinued operations, in line with the planned transition of Sanofi to a focused, science-driven biopharma company.

The revised financial data which were reviewed by Sanofi’s auditors, include details on sales, business net income and reported IFRS financials of Sanofi excluding Opella. From Q4 2024 and until the closing of the transaction, the profit or loss of Opella, net of tax, is included in “Net income / (loss) from discontinued operations” in the Sanofi income statement. This classification as discontinued operations as well as the full financial data apply to all previous quarters of 2024 and for comparison to all quarters of 2023.

Sanofi's Q4 2024 results, reflecting the new scope excluding Opella, are expected to be published on January 30, 2025.